PROTOCOL_ID_OR_DOCUMENT_NUMBER	TITLE	PHASE	LEAD_ORGANIZATION_CTEP_ID_COLON_PRINCIPAL_INVESTIGATOR_NES_ID_SEMICOLON_DELIMITED	AGENTS_SEMICOLON_DELIMITED	INVESTIGATOR_NES_ID_SEMICOLON_DELIMITEDINC07-10-01	"Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions: An Inter-Consortium Collaborative Study"	II	VA166:22248	Pioglitazone.HCl	22248;23084MAY03-1-02	"Randomized, Phase IIb Trial of Sulindac in Smokers with Bronchial Dysplasia"	II	02020:269650;02019:269720	Sulindac	22248;22248MAY03-1-03	"Randomized, Phase II Trial of Atorvastatin, RAFTILOSE Synergy 1, and Sulindac Among Patients at Increased Risk for Sporadic Colorectal Neoplasia"	II	02022:22248	Atorvastatin Calcium;Inulin;Sulindac	22248;23084MAY03-1-BIO	Bioequivalency Study of Sulindac in Capsule versus Tablet Formulations	N/A		Sulindac	22248;23084MAY04-4-01	"Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole + Two Doses of Aspirin in Barrett's Esophagus Patients"	II	02002:22248;03001:23084;02018:22248	Antacid Preparation;Aspirin;Esomeprazole Magnesium	22248;23084MAY06-8-01	Phase IIb Randomized Comparative Study of the Efficacy and Safety of Myo-inositol versus Placebo in Smokers with Bronchial Dysplasia	II	03001:22248	myo-Inositol	22248;23084MAY07-9-01	"Single-Dose Phase 0 Exploratory Pharmacokinetic Clinical Trial Comparing Five Oral Formulations of SR13668, an Orally Active AKT Pathway Inhibitor"	0	02018:23084	SR13668	22248;23084MAY08-12-02	"Randomized, Double-Blind, Phase II Chemoprevention Trial of DFMO and Sulindac among Women with Germline Mutations in BRCA1"	II		Eflornithine.HCl;Sulindac	22248;23084MAY09-14-01	"Phase 0, Dose-Escalation Trial of SP-333 to Demonstrate Colorectal Bioactivity in Healthy Volunteers"	0	02018:22248	Guanylate Cyclase C Agonist SP-333	22248;23084MAY10-15-02	Pioglitazone as a Candidate Chemoprevention Agent for Lung Cancer: A Pilot Trial Using a Pre-Surgical Model in Early Stage NSCLC	N/A	02018:22248	Pioglitazone.HCl	22248;23084MAY10-15-03	Randomized Double Blind Placebo Controlled Phase II Trial of Barrett's Esophagus Chemoprevention with Metformin	II	02018:22248	Metformin Hydrochloride	22248;23084MDA03-1-01	"Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Study of Polyphenon E in Patients with Barrett's Esophagus"	I	02018:22248;02001:22248	Green Tea Catechins	22248;23084MDA03-1-03	A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride versus Placebo for Patients with Clinically Organ-Confined Prostate Cancer	II	02001:269510	Finasteride	22248;23084MDA04-2-02	Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia	II	02001:22248	Rosiglitazone Maleate	22248;23084MDA04-3-01	Phase II Placebo Controlled Trial of Preoperative Lycopene Supplementation in Prostate Cancer Patients	II	02001:22248;02022:22248	Lycopene	22248;23084MDA04-3-03	Phase I Study of Aminolevulinic Acid and Photodynamic Therapy in Patients with Barrett's Esophagus and High-Grade Dysplasia	I	02022:22248	Aminolevulinic Acid Hydrochloride	22248;23084MDA04-4-01	"Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with a History of Hormone Receptor-Negative Breast Cancer"	I	02022:22248	Green Tea Catechins	22248;23084MDA05-5-01	Randomized Phase II Trial of Budesonide Turbuhaler 800 Micrograms/Twice Daily versus Placebo in High-Risk Population with Undetermined Lung Nodules Detected at Screening Low Dose CT Scan	II	02022:22248	Budesonide	22248;23084MDA05-5-03	Evolution of Undetermined ld-CT Detected Lung Nodules among a Randomized Phase II Trial with Inhaled Budesonide	II	02022:22248		22248;23084MDA05-6-01	A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer	I	02022:23084	Atorvastatin Calcium	22248;23084MDA09-13-01	Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers	I/II	02022:23084	Celecoxib;Zileuton	22248;23084MDA10-16-01	A Multicenter Phase II Trial of PARP Inhibitor ABT-888 in Triple Negative Breast Cancer Survivors	II	02022:22248;03001:23084	Veliparib	22248;23084NWU03-1-04	Phase IIb Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer	II	03001:22248	G-2535 (Isoflavones 100)	22248;23084NWU04-2-03	Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia	II	03001:22248	Aspirin	22248;23084NWU04-4-01	Phase IIb Trial of ADT in Subjects with Bronchial Dysplasia	II	03001:23084	Anethole Trithione	22248;23084NWU04-4-02	Phase I Study of Single Oral Dose of Se-Methyl-Seleno-L-Cysteine (MSC) in Adult Men	I	03001:22248	L-Se-Methylselenocysteine	22248;23084NWU05-5-01	A Phase I Trial of ALA PDT for Treatment of Oral Leukoplakia	I	03001:22248	Aminolevulinic Acid Hydrochloride	22248;23084NWU06-8-01	Polyethylene Glycol for ACF Reduction and Biomarker Modulation in Individuals with CRC Risk	II	03001:22248	Polyethylene Glycol	22248;23084NWU07-9-02	Pre-surgical Phase IIB Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women with Duct Carcinoma in Situ of the Breast	II	03001:22248;02020:22248	4-Hydroxytamoxifen;Tamoxifen Citrate	22248;23084NWU08-11-01	A Phase I Study of Erlotinib in Patients with Premalignant Lesions of the Lung	I	02020:23084	Erlotinib.HCl	22248;23084NWU09-13-02	Myo-Inositol Chemoprevention in Colitis-Associated Dysplasia	I/II	02020:22248	myo-Inositol	22248;23084NWU09-4-03	Phase I Multiple Dose Study of 12-Week Treatment by Se-Methyl-L-Cysteine(MSC) and L SeMet in Adult Males	I	02020:22248	L-Se-Methylselenocysteine;l-Selenomethionine	22248;23084UAZ03-1-02	A Phase II Trial of Polyphenon E for Cervical Cancer Prevention	II	02020:23084	Green Tea Catechins	22248;23084UAZ04-2-01	"Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Resiquimod for Atypical Nevi."	II	02020:22248	Resiquimod	22248;23084UAZ04-2-02	Phase 1B Sulindac Study for Women at High Risk for Breast Cancer	I		Sulindac	22248;23084UAZ05-2-09	Phase I Safety Study of Resiquimod for Atypical NevI	I	02020:22248	Resiquimod	22248;23084UAZ05-2-10	Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma	II	02020:23084	Sulindac	22248;23084UAZ05-6-01	Phase Ib Study of Polyphenon E in a Pre-prostatectomy Prostate Cancer Cohort	I		Green Tea Catechins	22248;23084UAZ06-8-01	Clinical Study of Resveratrol on Drug and Carcinogen Metabolizing Enzymes	I	02020:22248	Resveratrol	22248;23084UAZ07-10-02	"A Randomized, Double-blind, Placebo-controlled Phase II Trial of 3,3'-Diindolylmethane for High-Grade Cervical Intraepithelial Neoplasia"	II	02020:22248	"3,3'-Diindolylmethane"	22248;23084UAZ07-9-09	"Phase II, Randomized, Placebo-Controlled Trial of Imiquimod for Atypical NevI"	II	02020:23084	Imiquimod	22248;23084UAZ08-11-01	Clinical Study of Ursodeoxycholic Acid in Barrett's Patients	II	02020:22248	Ursodiol	22248;23084UAZ08-12-01	Pilot Study of Resveratrol in Postmenopausal Women with High Body Mass Index	N/A	02020:23084	Resveratrol	22248;23084UAZ08-12-02	Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer	I	02020:22248	Letrozole	22248;23084UAZ10-16-01	Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort	II	02020:22248;02002:22248	Metformin Hydrochloride	22248;23084UAZ10-16-03	Pilot Study on the Bioactivity of Vitamin D in the Skin after Oral Supplementation	I	02002:23084	Cholecalciferol	22248;23084UCI03-1-01	"A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology"	II	02002:22248	Lovastatin	22248;23084UCI04-2-01	Phase IIA Trial of Curcumin Among Patients with Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)	II	02002:23084	Curcumin	22248;23084UCI04-3-01	"A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients with Hepatitis C and Moderately Elevated AFP"	II	02002:22248	S-Adenosyl-l-methionine	22248;23084UCI05-5-01	Phase IIA Trial Testing Erlotinib as an Intervention Against Intraductal Pancreatic Mucinous Neoplasms	II	02002:22248	Erlotinib.HCl	22248;23084UCI06-8-01	"A Phase IIA Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon"	II	02002:22248	Erlotinib.HCl	22248;23084UCI09-13-01	A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Patients with a History of Colorectal Adenomas and Elevated Body Mass Index	II	02002:22248	Metformin Hydrochloride	22248;23084UWI03-1-01	Phase II Study of Isoflavone G-2535 (Genistein) in Patients with Bladder Cancer	II	02002:22248	Genistein	22248;23084UWI05-6-01	Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer	II	02002:22248	Acolbifene.HCl	22248;23084UWI05-7-01	Phase Ib Placebo-Controlled Trial of Diindolylmethane (BR-DIM) in the Study of the Modulation of Intermediate Endpoint Markers in Patients with Prostate Cancer who are Undergoing Prostatectomy	I	02002:22248	"3,3'-Diindolylmethane"	22248;23084UWI06-8-01	"A Phase II Randomized, Placebo-Controlled Trial of Polyphenon E to Evaluate Bladder Tissue Levels of EGCG"	II		Green Tea Catechins	22248;23084UWI06-8-02	"A Randomized, Double-Blind, Single-dose and Multi-dose Study of the Novel Retinoid, 9cUAB30 to Determine Pharmacokinetics and Safety"	I	02002:22248	9-cis-UAB30	22248;23084UWI06-8-03	"A Pilot Study of the Novel Retinoid, 9cUAB30 to Determine Preliminary Pharmacokinetics"	N/A	02002:22248	9-cis-UAB30	22248;23084UWI09-14-01	"Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men with Early Stage Prostate Cancer Undergoing Prostatectomy"	II	02002:22248	Cholecalciferol;G-2535 (Isoflavones 100)	22248;23084UWI09-8-02	"A Randomized, Double-Blind, Single-Dose and Multi-Dose Study of the Novel Retinoid, 9cUAB30 to Determine Pharmacokinetics and Safety"	I	02002:22248	9-cis-UAB30	22248;23084UWI10-16-01	A Phase IIa Skin Cancer Chemoprevention Trial of 9cUAB30 in Participants at High Risk for Non-melanoma Skin Cancer	II	02002:22248	9-cis-UAB30	22248;23084UWI11-16-01	"A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/Pomx in Subjects with Clinically Localized Prostate Cancer Undergoing Active Surveillance"	II		"Pomegranate Fruit (edible and/or inedible portions, extractive, and digests)"	22248;23084